Respinova

Novel Treatment for COPD and Inhaled Therapeutics

Health Tech & Life Sciences
Non Active, Mar 2025 ceased to operate
Series A Herzliya, Israel Founded 2008
LinkedIn
Last updated 2026-06-18
Total raised
$7.8M
Last: Grant 2019-02
Stage
Series A
Founded
2008
Headcount
1
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

Respinova has developed the PulseHaler, a noninvasive technology that aims to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD). The PulseHalers proprietary multi-frequency air pressure pulse technology is an easy-to-use treatment intended for patients diagnosed with COPD of all severity stages. The companys technology was successfully validated in two clinical studies. The first study demonstrated PulseHalers ability to improve the lung function, exercise capacity, and quality of life of COPD patients. The second study demonstrated the technologys ability to deliver drugs more effectively to the lung periphery. The PulseHaler stands alongside leading COPD drugs in managing the disease and enhancing the patients functional capacity and quality of life and has the potential to become a standard of care in COPD management. The commercialization of PulseHaler was co-funded by the European Unions Horizon 2020 program. The device was granted an FDA 510(k) clearance in April 2021.

Funding history · 4 rounds · $7.8M total

2019-02
Grant $2.7M
2018-03
$2.5M
2017-12
Grant $60K
2012-01
$2.5M

Q&A

What is Respinova's current operational status?
Respinova is currently inactive, having ceased operations in March 2025.
What is Respinova's primary product?
Respinova developed the PulseHaler, a noninvasive technology designed to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD) using multi-frequency air pressure pulse technology.
When was the PulseHaler granted FDA clearance?
The PulseHaler was granted FDA 510(k) clearance in April 2021.
How much funding has Respinova raised in total?
Respinova has raised a total of $7,760,000 across its funding rounds.
Which organization co-funded the commercialization of the PulseHaler?
The commercialization of the PulseHaler was co-funded by the European Union's Horizon 2020 program.
When did Respinova receive its most recent funding?
Respinova received its most recent funding, a Grant round, in February 2019 for $2,700,000.
Who is the founder and CTO of Respinova?
Yuval Avni is the Founder & CTO of Respinova.

Team · 1

Founder · Founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2BB2CB2B2C

Highlights

1 PatentsVerified

Tags

medical-deviceshospitalshome-careasthmanon-invasivedrug-deliveryinhalationpulmonaryrespiratorypatientschronic-patientstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/27163196

Identifiers & details

Founded2008-9
Employees (exact)1
Status reasonNon Active, Mar 2025 ceased to operate